CRISPR's diabetes cell therapy trial ends early
NCT ID NCT05565248
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new treatment called VCTX211 for people with type 1 diabetes. The goal was to see if implanting these special cells could help the body make insulin and reduce the need for insulin shots. Only 5 people took part, and the study was stopped early. The main focus was on safety and whether the treatment worked.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Alberta
Edmonton, Alberta, Canada
-
University of British Columbia
Vancouver, British Columbia, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Quitting smoking may also ward off diabetes — a trial puts the dual strategy to the test
- Could a simple clinic Check-In change catch hidden high blood pressure and diabetes?
- Smart insulin pump may boost brain and body health in older adults with diabetes
- Childhood brain tumor survivors face hidden hormone risks years later
- Decades-Long study of 121,700 nurses aims to uncover hidden heart disease triggers
- Could donating blood help control diabetes and fatty liver?